Terns Pharmaceuticals, Inc.

NASDAQ•TERN

CEO: Ms. Amy L. Burroughs M.B.A.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-02-05

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

連絡先情報

1065 East Hillsdale Boulevard, Suite 100, Foster City, CA, 94404, United States

650-525-5535

www.ternspharma.com

時価総額

$3.99B

PER (TTM)

-43.0

17.5

配当利回り

52週高値

$48.26

52週安値

$1.87

52週レンジ

91%

順位50Top 68.9%

3.1

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 3.1 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.27-3.57%

直近4四半期の推移

フリーCF

-$19.77M+20.16%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

TERN-701 Clinical Data Update Nine-month data shows 75% cumulative MMR rate by 24 weeks in CARDINAL trial efficacy-evaluable patients.

Cash Runway Secured Cash reserves of $150.7M are sufficient to fund planned operating expenses and capital requirements into 2028.

R&D Investment Rises Nine-month R&D expenses increased $6.9M to $59.0M, driven by clinical and preclinical program advancement.

Stock-Based Costs Decline Total stock-based compensation expense was $10.0M for nine months, decreasing from $12.6M prior period.

リスク要因

Regulatory Agency Disruption FDA funding cuts and potential government shutdowns could hinder timely guidance and product approval timelines.

Metabolic Asset Pivot Company decided not to advance TERN-601 or invest further in TERN-501 or the TERN-800 series assets.

Substantial Future Funding Expect continued net operating losses requiring substantial additional funding to support ongoing research and development activities.

Trade Policy Uncertainty Evolving global trade policies and tariffs, especially concerning China operations, pose risks to supply chain costs.

見通し

Focus on TERN-701 Advancement Strategy reiterates rapid advancement of TERN-701 program across all Chronic Myeloid Leukemia treatment lines.

Seeking TERN-501 Partner Actively seeking strategic partner to advance TERN-501 program for obesity and other metabolic disorders.

Increased Operating Expenses Expect expenses to increase as development continues for ongoing clinical trials and future regulatory submissions.

同業比較

売上高 (TTM)

ARVN

$262.60M

-0.3%

SNDX

$172.35M

+627.8%

DAWN

$158.18M

+20.6%

粗利益率 (最新四半期)

SNDX

102.3%

-13.9pp

RLAY

91.4%

+0.0pp

URGN

91.3%

-2.2pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ERAS	$4.54B	-33.4	-34.5%	11.9%
TERN	$3.99B	-43.0	-30.0%	0.3%
DAWN	$2.20B	-20.5	-23.4%	0.5%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月19日

EPS:-$0.29

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし